XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filing - 1/11/2012

Effective Date 1/11/2012

XNAS:JAZZ Fair Value Estimate
Premium
XNAS:JAZZ Consider Buying
Premium
XNAS:JAZZ Consider Selling
Premium
XNAS:JAZZ Fair Value Uncertainty
Premium
XNAS:JAZZ Economic Moat
Premium
XNAS:JAZZ Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
FALBERG KATHRYN E
  2. Issuer Name and Ticker or Trading Symbol
JAZZ PHARMACEUTICALS INC [JAZZ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP and CFO
(Last)
(First)
(Middle)
C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE
3. Date of Earliest Transaction (Month/Day/Year)
01/11/2012
(Street)

PALO ALTO, CA 94304
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/11/2012   M   45,580 A $7.35 49,008 D  
Common Stock 01/11/2012   F(1)   24,634 D $48.6 24,374 D  
Common Stock 01/11/2012   M   56,250 A $11.48 80,624 D  
Common Stock 01/11/2012   F(1)   33,342 D $48.6 47,282 D  
Common Stock 01/11/2012   M   40,000 A $27.46 87,282 D  
Common Stock 01/11/2012   F(1)   29,081 D $48.6 58,201 D  
Common Stock               53,000 I By Kathryn E Falberg Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) $7.35 01/11/2012   M     45,580   (2)(5) 12/06/2019 Common Stock 45,580 $ 0 54,420 D  
Option (right to buy) $11.48 01/11/2012   M     56,250   (3)(5) 03/07/2020 Common Stock 56,250 $ 0 3,750 D  
Option (right to buy) $27.46 01/11/2012   M     40,000   (4)(5) 03/09/2021 Common Stock 40,000 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
FALBERG KATHRYN E
C/O JAZZ PHARMACEUTICALS, INC.
3180 PORTER DRIVE
PALO ALTO, CA 94304
      SVP and CFO  

Signatures

 /s/ Carol A. Gamble as attorney-in-fact for Kathryn E. Falberg   01/13/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents shares withheld by the Issuer for cashless exercise of nonstatutory stock options solely to cover exercise price and required withholding taxes.
(2) This option, consisting of a nonstatutory stock option exercisable for 45,580 shares of common stock and an incentive stock option exercisable for 54,420 shares of common stock, has a vesting schedule of one fourth vested on December 1, 2010 and the remainder vesting in 36 equal monthly installments thereafter.
(3) This option, consisting of a nonstatutory stock option exercisable for 56,250 shares of common stock and an incentive stock option exercisable for 3,750 shares of common stock, has a vesting schedule of one fourth vested on March 8, 2011 and the remainder vesting in 36 equal monthly installments thereafter.
(4) This nonstatutory stock option has a vesting schedule of one fourth vesting on March 1, 2012 and the remainder vesting in 36 equal monthly installments thereafter.
(5) On October 24, 2011, the Board of Directors of the Issuer approved the full vesting of unvested nonstatutory stock options held by the Issuer's officers and non-employee directors, including the Reporting Person. Such vesting acceleration became effective on December 13, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filling

Jazz Pharmaceuticals PLC XNAS:JAZZ Stock - Get Insider Activity SEC Filing of Jazz Pharmaceuticals PLC XNAS:JAZZ stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filing - 1/11/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filing - 1/11/2012  |  Next: XNAS:JAZZ Jazz Pharmaceuticals PLC Insider Activity 4 Filing - 1/11/2012